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Abstract
Antibodies in sera from newly diagnosed insulin-dependent di-
abetes mellitus (IDDM) patients are directed to a human islet
cell protein of relative molecular mass (Mr) 64,000. Since Il)DM
seems to develop after a prodromal period of ,8-cell autoimmunity,
this study has examined whether 64,000 Mr antibodies could be
detected in 14 individuals who subsequently developed IDDM
and five first degree relatives who have indications of altered (3-
cell function. Sera were screened by immunoprecipitation on total
detergent lysates of human islets and positive sera retested on
membrane protein preparations. Antibodies to the 64,000 Mr
membrane protein were consistently detected in 11/14 IDDM
patients, and in all 5 first degree relatives. 10 IDDM patients
were already positive in the first samples, obtained 4-91 mo
before the clinical onset ofIDIM, whereas 1 patient progressed
to a high 64,000 M, immunoreactivity, at a time where a com-
mencement of a decline in (3-cell function was detected. 64,000
M, antibodies were detected before islet cell cytoplasmic anti-
bodies (ICCA) in two patients. In the control groups of 21 healthy
individuals, 36 patients with diseases of the thyroid and 5 SLE
patients, the 64,000 Mr antibodies were detected in only one
individual, who was a healthy sibling to an IDDM patient. These
results suggest that antibodies against the Mr 64,000 human
islet protein are an early marker of (-cell autoimmunity and may
be useful to predict a later development of IDDM.
Introduction
The clinical onset of insulin-dependent diabetes mellitus
(IDDM)' is associated with a specific loss of the H-cells in the
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1. Abbreviations used in this paper: FBS, fasting blood sugar; FITC,
fluoresceine isothiocyanate; ICCA, islet cell cytoplasmic antibodies; ICSA,
islet cell surface antibodies; IDDM, insulin dependent diabetes mellitus;
IVGTT, intravenous glucose tolerance test; NCS, newborn calf serum;
NHS, normal human serum; OGTT, oral glucose tolerance test; PAGE,
polyacrylamide gel electrophoresis; SLE, systemic lupus erythematosis;
TBTE, 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 0.5 mM methionine,
islets of Langerhans and autoimmune phenomena may play a
role in the pathogenic process. A majority of newly diagnosed
IDDM patients have islet cell surface antibodies (ICSA) and/or
cytoplasmic antibodies (ICCA) (1). Infiltrating lymphocytes are
present in the pancreatic islets (2) and there is evidence for hy-
persensitivity towards pancreatic antigens (3).
The nature of the primary (i-cell target antigen(s) re-
mains to be elucidated. Immunoprecipitation of lysates of
[35S]methionine labeled human islets showed that newly diag-
nosed diabetic children had antibodies to a relative molecular
mass (Me) 64,000 protein (4). In the spontaneously diabetic BB
rat, which develops IDDM similar to the human disease, anti-
bodies to a rat islet cell 64,000 Mr protein were also found to
appear between 12 and 22 d of age (5, 6), which is before the
detection of both insulitis (around day 65) (7), decrease in 13-
cell mass and function (day 45-50) (8, 9) and the subsequent
onset ofIDDM at or beyond 60-70 d of age.
IDDM in man seems to develop after a long latency period,
which is reflected both in a decreased first-phase insulin release
after intravenously administered glucose (10-13) and in the ap-
pearance of ICCA (14-16), which precedes the clinical onset of
IDDM up to several years. Our hypothesis is that the 64,000 Mr
protein is a primary target autoantigen. In this study we have
therefore tested whether carefully documented individuals fol-
lowed before their clinical onset ofIDDM (10-15, 17) and first
degree relatives with signs ofimpaired (3-cell function, had 64,000
Mr antibodies. Control groups including healthy siblings to
IDDM patients, healthy individuals with no family history of
IDDM and patients with other autoimmune diseases were tested
as well.
Methods
Isolation of islets. Human islets of Langerhans were isolated from the
pancreata of 18 cadaver kidney donors at the University Hospitals of
Copenhagen (male/female ratio 9:9, 14-60 yr ofage). HLA-typing showed
HLA-DR 1 in 3, DR 2 in 6, DR 3 in 4, DR 4 in 4, DR 5 in 2, DR 6 in
3, and DR 7 in four pancreata. One pancreas was not tissue typed. Iso-
lation ofhuman islets by collagenase digestion and selection of individual
islets under a stereomicroscope was carried out as described (18). The
islets were cultured for 1 d in RPMI 1640 medium supplemented with
0.35 g per liter NaHCO3, 20 mM Hepes, 10% (vol/vol) newborn calf
10 mM benzamidine/HCl, 1% Trasylol, 5 mM EDTA, 0.1 mM p-chlo-
romercuribenzenesulfonic acid; TNMB buffer, 20 mM Tris/HCl (pH
7.4), 150 mM NaCI, 0.5 mM methionine, 10 mM benzamidine/HC1;
TN-1 14, Triton X-1 14.
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serum (NCS), 100 U ml 1 penicillin and 100 ,g ml-' streptomycin. After
being reselected and transferred individually to fresh medium supple-
mented with 0.5% normal human serum (NHS) instead of NCS, the
islets were kept in culture (100 islets/4 ml) for 5-10 d. The release of
insulin was measured by radioimmunoassay using porcine insulin (Nor-
disk Gentofte, Gentofte, Denmark) as standard.
Preparation oflabeled cell extracts. Cultured islets were washed twice
by centrifugation (2 min, 200g) in methionine-free RPMI 1640 medium
supplemented with 16 mM glucose, 2% NHS, penicillin, and strepto-
mycin. Islets (500 islets/ml) were first incubated in this medium for 60
min before [35S]methionine (0.5 mCi/ml, New England Nuclear, Boston
MA; > 500 Ci/mmol) was added. After incubation for 4-6 h at 370C,
the labeled islets were harvested by centrifugation, washed twice in RPMI
1640 medium containing 0.5 mM methionine and once in TNMB buffer.
The islets were resuspended (1,000 islets/ml) in TNMB supplemented
with 1% Trasylol (Novo Industries, Bagsvord, Denmark), 5 mM EDTA
and 0.1 mM p-chloromercuribenzenesulfonic acid (Sigma Chemical Co.,
St. Louis, MO) (TBTE buffer) and 1% Triton X-l 14 (TN-1 14) (Sigma
Chemical Co.) precondensed as described by Bordier (19). The suspension
was incubated on ice for 2-4 h to solubilize the islets and then centrifuged
at 100,000 g for 30 min. The lysate supernatant was either used for
immunoprecipitation directly or after separation of amphiphilic mem-
brane proteins from hydrophilic proteins by phase separation (19).
Phase separation. The TN- 1 14 lysate was layered over a cushion of
TBTE buffer containing 6% (wt/vol) sucrose and 0.2% TN-1 14 in a sil-
iconized tube. The TN-l 14 was condensed by incubation at 30'C for 3
min and collected by centrifugation (3 min, 1,500 g) at 30'C as a 17%
detergent droplet below the sucrose cushion. The aqueous phase was
reextracted twice with 0.5% TN-l 14 and layered over the original sucrose
cushion. TBTE buffer was added to the combined detergent droplets to
give a final 1% detergent concentration.
Immunoprecipitation. Total TN-l 14 lysates or phase separated lysates
were pretreated for I h on ice with NHS followed by 30 min incubation
with protein A-Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala,
Sweden). The immunosorbent was removed by centrifugation and ali-
quots of the supernatant (100-200 Ml containing 5-19 X 106 cpm in
total extracts or 5-8 X 106 cpm in samples prepared by detergent phase
separation) incubated with 25 Ml serum for 16 h followed by incubation
with 100 Ml preswollen protein A-Sepharose. The immunoprecipitates
were washed six times by centrifugation in 2 ml TNMB-buffer containing
0.5% TN-I 14 and once in ice-cold double distilled and autoclaved H20
containing 0.02% (wt/vol) Trasylol. Bound proteins were eluted from
the immunosorbent by I min boiling in 80 mM Tris/HCl, (pH 6.8),
containing 3% SDS, 15% sucrose, 5% 2-mercaptoethanol and 0.006%
bromphenol blue.
Gel electrophoresis. Immunoprecipitated proteins were separated ac-
cording to molecular weight by discontinuous sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) as described by
Laemmli (20) using 7.5-15% linear acrylamide gradient gels. The gels
were stained with Coomassie Brilliant Blue and processed for fluorography
using Enlightning (New England Nuclear) and Kodak X-omat AR film.
Mr standards (Pharmacia Fine Chemicals) used were phosphorylase b
(94,000), bovine serum albumin (67,000), catalase (60,000), ovalbumin
(43,000), carbonic anhydrase (30,000), trypsin inhibitor (20,100), and
lactalbumin (14,400).
Human sera. Sera were obtained from 14 IDDM patients (Table I)
who had been carefully studied before the clinical onset by being mono-
zygotic twins or a monozygotic triplet (patients 1, 3, 6, 11, 12, 14, and
5, respectively) (10, 11, 17), or healthy siblings to IDDM patients (patients
2, 8, 9) (15).2 Patients 4 (15), 7, 10, and 13 were referred due to a history
of transient hyperglycemia and/or glucosuria. IDDM was diagnosed ac-
cording to the World Health Organization (WHO) criteria of clinical
onset (21). Sera were also obtained from five first degree relatives: siblings,
2. De Beaufort, C. E., N. C. Den Boer, G. J. Bruining, R. van Strik, and
T. Weterings. Submitted for publication.
including one twin, and three parents ofIDDM patients having signs of
altered (i-cell function (Table II). The control group consisted of sera
from 16 healthy siblings to IDDM patients, including 2 twins and 1
triplet and from 5 healthy laboratory staff members without a family
history of IDDM (Table III). 10 of the controls (C 12-21) were siblings
to the IDDM patients participating in this study (Table I). Four control
individuals (C 1-4) were selected from a group of 16 tissue-typed siblings
to IDDM children participating in a Swedish family study on the basis
ofHLA-DR identity to at least one ofthe IDDM patients studied (Table
I). Two control siblings (C 5 and 6) were selected on a random basis
from a group of nontissue-typed siblings to Danish IDDM patients. Dis-
ease specificity was tested by immunoprecipitation with sera from five
patients with systemic lupus erythematosus (SLE) having nuclear antibody
titers of 32-1024 as measured in an immunofluorescence assay and DNA-
antibody titers of 12-45% measured in a Farr immunoprecipitation assay
(information and sera kindly provided by Dr. V. Andersen, University
of Copenhagen). Furthermore sera from 34 patients with Hashimoto's
or Graves' disease were tested. 18 sera were from Copenhagen and in-
cluded 12 Graves' and 6 Hashimoto's disease patients having microsomal
antibody titers of0-640 as measured by immunofluorescence on frozen
sections of human thyroid tissue (in which a titer of 640 is the highest
measured) and some having thyroglobulin antibody titers . 200,000
measured in an agglutination assay (sera and information kindly provided
by Drs. K. Bech and U. Feldt-Rasmussen, Frederiksberg Hospital, Co-
penhagen). 16 sera were from Cardiff and included 6 Graves' and 10
Hashimoto's disease patients. The Graves disease patients had thyrotro-
pin-stimulating hormone receptor antibodies varying from low to very
high. The Hashiomoto's patients had microsomal antibody titers of 1.6-
1.9 in an enzyme-linked immunosorbent assay (in which a titer of 1.8
corresponds to an agglutination assay titer 2 10,000) (sera and infor-
mation kindly supplied by Dr. Allan McGregor, University of Cardiff).
Furthermore sera were tested from one patient with atoxic diffuse and
one patient with toxic adenom of the thyroid.
All sera were centrifuged at 10,000 g for 30 min, aliquoted and kept
at -20'C. Coded sera from 5 monozygotic twins/triplets (P1, 3, 5, 11,
12), 5 first degree relatives (R 1-5), 16 thyroiditis patients, and 3 controls
(C8, 9, 14) were initially scored in a "blinded" fashion with the subject
category assigned after analysis of the assay results.
Islet cell cytoplasmic antibodies. ICCA were analyzed in all the Eu-
ropean patients and controls (Tables I-III), using cryostat sections of
human blood group 0 pancreata and a novel, highly sensitive two-color
immunofluorescence assay with Texas red labeled proinsulin antibody
and fluorescein isothiocyanate (FITC)-labeled antibody to human IgG
(22). All the United States patients and controls had been tested previously
by the FITC-labeled protein A-monoclonal antibody method (23), and
sera were not available for retesting by the two-color assay.
Results
Membrane protein characteristics ofthe Mr 64,000 protein. The
Mr 64,000 protein partitioned into the detergent phase of TN-
1 14 after phase transition at 30°C. The detergent phase con-
taining amphiphilic membrane proteins (24) constituted 8-10%
of total TCA precipitable counts in human islet cell lysates. As
shown in Fig. 1, the partition could be used to purify the 64,000
Mr protein before immunoprecipitation, resulting in an effective
removal of background proteins.
Human islet preparations and the immunoprecipitation as-
say. The islet preparations released 3.8±2.9 ng insulin/islet per
d (mean±SD). A positive correlation between the expression of
the 64,000 Mr antigen and the insulin releasing capacity of the
islet preparations was found (data not shown). Therefore, all
sera from each individual were tested in parallel at least once
on the same islet preparation, and the intensity of immunopre-
cipitated 64,000 Mr antigen on autoradiograms compared. Sera
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Table I. IDDM Patients Analyzedfor 64,000 Antibodies in the Prediabetic Period
Age at clinical Indication for Prediabetic period
Patient Origin Sex HLA-DR onset of IDDM observation followed ICCA* a64,000*
mo
I USA M 3, x 48 Monozygotic twin 78-5 2+ 3+
2 NL F 3, 4 14 IDDM family study 32-0 2 64 3+
3 USA F 3, 4 11 Monozygotic twin 21-2 4+ 3+
4 NL M 3, 4 3 Glucosuria 4-0 64 3+
5 USA M 4, x 21 Monozygotic triplet 91-7 2+ 2+
6 DK M 3, 7 26 Monozygotic 25-7 264 2+
7 DK F 4, w6 13 Glucosuria 4-0 64 2+
8 NL M 1,4 19 IDDM family study 28-0 264 1+
9 NL M 3, w9 17 IDDM family study 16-4 64 i+
10 DK M 4 24 Glucosuria 24-0 .64
11 USA F 1,7 13.5 Monozygotic twin 12-1 - +
12 USA F NT 28 Monozygotic twin 84-48 + +
13 DK M NT 18 Glucosuria 22-0 2+
14 S M 1,4 18 IDDM family study 25-0 64 2+
* ICCA in the USA patients are expressed on a scale 0-4+. ICCA in sera from Denmark (DK), Sweden (S), and the Netherlands (NL) are ex-
pressed as the highest dilution at which sera were still positive. t Positivity of 64,000 M, antibodies was designated very strong: 3+, strong: 2+,
and weak: 1+. The positivity of the strongest positive serum during the observation period is listed.
from different patients were also tested in parallel and compared
to positive and negative control sera. All serum samples were
screened on total detergent lysates from at least two different
islet preparations. Fig. 2 shows the immunoprecipitation ofcrude
islet cell lysates using sera from IDDM patients 6, 7, 9, 13, and
14 together with sera from healthy controls (C1, 3) and a first
degree relative with indications of a decreased (-cell function
(R3). Differences in immunoreactivity of 64,0Q0 Mr antibody
positive sera are clearly apparent and were consistently detected.
Immunoreactivity ofsera was estimated as intensity ofthe 64,000
Mr band on autoradiograms and scored on a 0-3+ scale. All
positive sera were further analyzed using TN-1 14 detergent phase
purified membrane proteins to increase the specificity of the
assay and verify that they recognized the 64,000 Mr membrane
protein.
Analyses of 64,000 M, antibodies in IDDM patients. Sim
from 11 of 14 IDDM patients consistently immunoprecipitated
the 64,000 Mr protein (Table I) when tested on both total lysates
and a TN- 1 14 detergent phase purified membrane protein frac-
tion.
Four of the IDDM patients (patients 1-4) had antibodies
that repeatedly precipitated a very strong 64,000 Mr band des-
ignated 3+, five patients (patients 5-7 and 13, 14) immunopre-
cipitated a strong band, designated 2+, two patients (patients 8
and 9) immunoprecipitated a weak 64,000 Mr band designated
1+, patients 11 and 12 were either weakly positive or negative
in the multiple testings, and patient 10 was negative.
Analyses of64,000 M, antibodies in first degree relatives of
IDDM patients having inaications ofa decreased fl-cellfunction
and/or ICCA. Individuals 1-5 (Table II) are first degree relatives
of IDDM patients obtained from the prospective Joslin predi-
abetes study on the basis of ICCA positivity (25). Relatives 1,
2, 4, and 5 exhibited first phase insulin release in response to
intravenously administered glucose lower than the 95th percen-
tile. Four individuals in this' group immunoprecipitated a very
strong (3+) 64,000 Mr band (Fig. 2, lane K, Fig. 3, lanes B-E),
and one a weak (1+) 64,000 Mr component (Fig. 3, lane A).
Analyses of64,000 M, antibodies in healthy individuals. This
group was comprised of 10 healthy siblings ofthe IDDM patients
included in this study, 6 healthy siblings to other IDDM patients,
and 5 individuals without IDDM in the family (Table III). Sera
from a healthy sibling to patient 10 immunoprecipitated a very
strong (3+) 64,000 Mr band from both crude 4ysates and TN-
1 14 detergent phase purified proteins. This individual was tested
and found to be positive for ICCA, but IVGTT showed no ab-
normalities.
Table II. First-Degree Relatives to IDDM Patients With Signs ofImpaired ,8-cell Function
Relation to IDDM Insulin release
Relative Origin proband(s) Sex Age ICCA* (percentile)t am64,OO
1 USA Sib and daughter F 34 4+ 3 1+
2 USA Parent F 58 4+ f 1 3+
3 USA Sib M 30 4+ 53 3+
4 USA Parent F 66 4+ <1 3+
5 USA Parent M 26 4+ 3 3+
* ICCA were measured on a scale from 0-4+. t References 11-14. a64,000 immunoreactivity was measured on a scale from 0 to 3+.
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Table IlI. Healthy Controls Testedfor 64,000 Mr Antibodies
Sibling to
Control Sex Age HLA D/DR patient no. ICCA a64,000
I M 16 3.7 - - -
2 F 13 3,4
3 F 15 4
4 F 19 3,4
5 F 11 NT -
6 F 15 NT
7 F 44 NT -
8 M 37 NT
9 M 34 NT
10 F 24 NT-
11 F 23 NT
12 M 16 3, 5 2
13 M 14 3,4 2
14 M 17 4,X 5
15 F 31 NT 6 -
16 F 10 NT 7 -
17 M 18 1,4 8
18 M 17 1, w6 8
19 F 14 1, w6 8 -
20 F 23 NT 9
21 M 21 NT 10 .64* 3+*
Controls 1-6 were healthy siblings to IDDM patients not included in
this study. Controls 2 and 5 are monozygotic twins to an IDDM pa-
tient. Controls 7-11 were laboratory staff members. Controls 12-21
were healthy siblings to the IDDM patients included in this study.
Control 14 is a triplet to patient 5. Sera from controls 15 and 21 were
obtained 34 and 7 mo, respectively, after onset ofIDDM in their sib-
ling. All the other sera were obtained before or at onset of IDDM in
the sibling. * ICCA expressed as dilution at which serum was still
positive. ta64,000 immunoreactivity expressed on a scale from 0
to 3+.
All other individuals in this group were Mr 64,000 antibody
negative (Table III, Fig. 1, lanes C, D, G, H, Fig. 2, lanes A, B,
Fig. 3, lane F).
Analyses of64,000 M, antibodies in serafrom SLE patients
andpatients with diseases ofthe thyroid. Five SLE patients were
tested and found to be negative for 64,000 Mr antibodies.
Sera from 16 Hashimoto's patients, 18 patients with Graves'
disease, one patient with atoxic diffse, and one patient with
toxic adenom were tested and found to be negative for 64,000
Mr antibodies. All these individuals were also tested for ICCA.
Only one of these patients was ICCA positive. Immunoprecip-
itates with some sera containing high titers ofthyroid microsomal
antibodies and crude human islet cell lysates had intensive back-
ground of nonspecifically precipitated proteins. Six ofthose sera
immunoprecipitated a fuzzy band at a slightly lower Mr than
the 64,000 protein band in the 64,000 Mr region (data not
shown). However, prolonged gel electrophoretic analyses sepa-
rated this band from the 64,000 Mr antigen, immunoprecipitated
by IDDM sera. Furthermore, the sera were negative on TN-1 14
detergent phase purified-membrane proteins demonstrating that
the protein they detected in crude lysates was not the 64,000 M,
membrane protein immunoprecipitated by IDDM sera. These
sera were tested in a group ofcoded sera and were scored negative
on the basis of those analyses. Those results demonstrate the
importance of using purified membrane proteins for 64,000 Mr
antibody analyses to avoid false positives.
Prospective analysis of 64,000 Mr antibodies in IDDM pa-
tients. The 14 IDDM patients included in this study had been
followed up to 4-91 mo before clinical onset of IDDM. Fig. 4
shows the 64,000 Mr antibody immunoreactivity and ICCA
analyses in the observation period of each patient. Patients 1-
6, 8, 10, 1 1, and 12 have been described in detail elsewhere with
regard to clinical parameters (10-15, 17).2
Case studies
Patient 1 (Fig. 4, Table I) (10, 11, 14) was the only 64,000 Mr
antibody positive patient which progressed from a negative to
64,000 Mr antibody positive state during the observation period.
When tested on total islet lysates, samples obtained 78 and 70
mo before the clinical onset were 64,000 Mr antibody negative.
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Figure 1. Fluorograph showing immunoprecipitation of human islet
cell proteins before and after TN-1 14 detergent phase purification with
sera from an HLA-DR 3/4 positive IDDM patient and two control in-
dividuals. Total islet cell lysates (lanes A-D) or an amphiphilic mem-
brane protein fraction purified by TN-1 14 phase separation of islet cell
lysates (lanes E-H) were immunoprecipitated with sera from patient
2, 32 mo before (lanes A and E) and at the clinical onset ofIDDM
(lanes B and F) and sera from controls 2 (lanes C and G) and 4 (lanes
D and H).
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Figure 2. Fluorograph showing variations of
64,000 M, immunoreactivity in sera from several
IDDM patients and a first degree IDDM relative.
Total islet cell lysates were immunoprecipitated
with sera from controls I (lane A) and 3 (lane B),
sera from patient 9 (lanes C-F) obtained 16, 10,
7, and 4 mo before clinical onset of IDDM, pa-
tient 7 (lanes H, I) 4 mo before and at clinical
onset of IDDM, patient 13 (lane J) 22 mo be-
fore, patient 14 (lane L) 25 mo before, patient 6
(lane M) 25 mo before clinical onset ofIDDM
and IDDM relative 3 (lane K). A 3+ positive
IDDM serum used as a control is shown in
lane G.
However, the latter sample showed a faint 64,000 Mr band when
tested on TN-1 14 detergent phase purified islet proteins. The
samples at 55 and 5 mo before the clinical onset were strongly
64,000 Mr antibody positive. The appearance ofhigh 64,000 M,
immunoreactivity in the 55-mo sample coincided with appear-
ance ofICCA ( 11) and a commencement ofa slowly progressing
decline in first-phase insulin release in response to intravenous
glucose (10, 11, 14).
Patient 2 (Fig. 4, Table I [15]) was strongly positive, (3+),
for 64,000 Mr antibodies, and ICCA 32 mo before and at the
clinical onset ofIDDM. Fig. 1 shows immunoprecipitations using
sera from this patient and two HLA-DR matched controls (DR
3, 4) on total lysates (lanes A-D) and TN-1 14 detergent phase
purified membrane proteins (lanes E-H).
Patient 3 (Fig. 4, Table I) (1 1, 13, 14) was strongly positive,
(3+), for 64,000 Mr antibodies 21 and 2 mo before the clinical
onset. ICCA (1 1, 13, 14) was also positive.
Patient 4 (Fig. 4, Table I) (15) was strongly 64,000 Mr an-
tibody and ICCA positive in samples obtained 4, 2, and 1 me
before and at the clinical onset of IDDM (15).
Patient 5 (Fig. 4, Table I) (10, 11, 14) was strongly 64,000
Mr antibody positive, (2+), in a sample obtained 91 mo before
clinical onset of IDDM, but became weakly positive in later
samples. He was ICCA positive during the whole observation
period (11). Compared with his nondiabetic triplet mate, he
showed a decrease of the first phase insulin release in response
to intravenous glucose at 91 mo and a further progressive loss
became apparent during the following years (10, 1 1).
Patient 6 (Fig. 4, Table I) (17) was strongly (2+) positive for
64,000 Mr antibodies already in the first sample (Fig. 2, lane M)
obtained when his twin brother developed IDDM, which oc-
cuffed 25 mo before the diagnosis of his own IDDM. He re-
mained strongly positive in four samples obtained before and
at clinical onset ofIDDM. He progressed from an ICCA negative
to a positive state in the third sample obtained 9 mo before
clinical onset of IDDM.
Patient 7 (Fig. 4, Table I) had intermittent glucosuria in
connection with a febrile infection 3 yr before and developed
persistent mild glucosuria 5 mo before the clinical onset of
IDDM. She was strongly (2+) positive for 64,000 Mr antibodies
930 Bwkkeskov et al.
A
4
._
94- _
67-
60-
43-
30-
20-
14-
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI112903
R-1 R-2R-3R-4R-5C-7 SERA
rnnrnn
A B C D E F
**4
,W.,-,,.Irwl, 4m
.0st., '.w-. Ow
0 I.W. ...
f'a
-o
D
(U
0
.0
c
.4
CD
-64
#1 DDM
X
78 55 5
#2 1DDM
32
#7 IDDM
*+ 0----<
+/- I
4
#5 0IDM
9142 ++
91 45 28 7
#6 1DDM
(;Cp 26 4
2
25 13 3
#9 I DDM
- >.264
16 10 4
60-
-w w V
43- 4,~- 4~2
30-
20-
14-
Figure 3. Fluorograph showing immunoprecipitation of the 64,000 M,
band with sera from first degree relatives ofIDDM patients. Total islet
cell lysates were immunoprecipitated with sera from relatives 1-5
(lanes A-E) and with serum from control 7 (lane F).
and ICCA in samples obtained 4 mo before and at the clinical
onset of IDDM (Fig. 2, lanes H, I).
Patient 8 (Fig. 4, Table I) (15) was weakly positive for 64,000
Mr antibodies in two samples obtained 28 mo before and at the
clinical onset of IDDM. He progressed from an ICCA negative
to a positive state in the period between the first sample and the
clinical onset.
Patient 9 (Fig. 4, Table 1)2 was followed at regular intervals
during a 1-yr period, starting 16 mo before the clinical onset of
IDDM. 64,000 Mr antibodies were positive in samples 2-4, 7-
10, while samples 1, 5, and 6 only immunoprecipitated a faint
64,000 Mr component (Fig. 2, lanes C-F). All samples precip-
itated an additional strong band at 94,000 M, (Fig. 2, lanes
C-F), which was detected as only a faint band in immunopre-
cipitates with other IDDM sera as well as control sera (Fig. 2,
lanes A, B, and G-M) and was absent when sera were tested on
#11 0IDDM #12 IDDM
12 1 8472 48
MONTHS BEFORE ONSET OF IDLLM
Figure 4. Time course of 64,000 M, antibodies and ICCA in the sub-
clinical phase of 14 IDDM patients. ICCA (open circle) were measured
either in a double immunofluorescence assay and results expressed as
the highest dilution at which sera were positive (patients, 2, 4, 6-10,
13, 14) or measured in a protein A immunofluorescence assay and re-
sults expressed on a scale from 0 to 4+ (patients 1, 3, 5, 11, 12) (10,
11, 13, 14). 64,000 M, antibody immunoreactivity (solid triangles)
was estimated on the basis of intensity of the 64,000 Mr antigen band
on autoradiograms and expressed on a scale from 0 to 3+.
TN-I 14 detergent phase purified-membrane proteins. This pa-
tient was positive for ICCA. in all but the last two samples.
Patient 10 (Fig. 4, Table I) came to our attention due to
intermittent glucosuria, hyperglycemia and impaired glucose
tolerance during a febrile infection 25 mo before clinical onset
ofIDDM. An oral glucose tolerance test showed impaired glucose
tolerance. A 10,000-kJ diabetes diet was initiated, and the con-
dition normalized. Fasting blood sugar was normal 2 wk later
and remained within normal range during the rest of the obser-
vation period. IVGTT performed 8 mo later showed a total loss
of first-phase insulin response. This patient was 64,000 Mr an-
tibody negative but ICCA positive during the observation period.
Patient 11 (Fig. 4, Table I) (11, 14) wasICCA negative during
the observation period. Sera obtained 12 and 1 mo before clinical
onset of IDDM were negative when tested on total islet cell
lysates. However, the first sample was weakly positive, when
tested on TN- 1 14 detergent phase purified islet cell proteins.
Patient 12 (Fig. 4, Table I) (11, 14) had been followed at 84,
72, and 48 mo before clinical onset of IDDM. 64,000 Mr anti-
bodies were negative when the sera were tested on total islet cell
lysates. The second serum sample was weakly positive, and the
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first and third serum samples were negative, when tested on TN-
114 detergent phase purified proteins.
Patient 13 (Fig. 4, Table I) had intermittent glucosuria and
showed impaired glucose tolerance 22 mo before the clinical
onset of IDDM. Serum samples obtained 22 mo before (Fig. 2,
lane J) and at the clinical onset were ICCA negative but strongly
positive for 64,000 Mr antibodies.
Patient 14 (Fig. 4, Table I) was the only ICCA positive in-
dividual among 57 siblings to IDDM children in a Swedish family
study. He was tested and found to be strongly 64,000 Mr antibody
positive (Fig. 2, lane L) IVGTT showed a lowered /3-cell function.
25-mo later, when he developed clinical symptoms of IDDM
and insulin was administered, he was still ICCA and 64,000 Mr
antibody positive.
Correlation between ICCA and 64,000 M, autoantibodies.
Comparison of 64,000 Mr antibody and ICCA assays in indi-
vidual patients (Fig. 4) shows that patients 1-9, and 14 were
positive in assays for both 64,000 Mr antibodies and ICCA. Pa-
tients 10 and 13 were discordant; patient 10 was ICCA positive
but 64,000 M, negative, and patient 13 was 64,000 Mr antibody
positve and ICCA negative during the observation period. 64,000
M, antibodies were clearly detected before ICCA in patients 6
and 8. Patients 11 and 12 were negative or weakly positive in
both assays indicating either that autoantibodies did not develop
in these patients or that they were present earlier (patient 11) or
later (patient 12) than the observation period. All 1st degree
relatives (Table II) and controls, except one Hashimoto's disease
patient, were concordant in both assays.
Discussion
Our results provide substantial evidence that antibodies to a
64,000 Mr human islet cell membrane protein (4) are associated
with development of IDDM.
All IDDM patients included in this study except patient 10
had a family history ofIDDM. In fact several ofthem had been
followed before the clinical onset ofIDDM for that reason. This
approach to study prodromal autoimmunity in IDDM was mo-
tivated by the fact that the prevalence of IDDM is only 0.4%.
However, the majority of new patients (87%) has no IDDM
family members.
In those highly selected individuals it was demonstrated that
the 64,000 Mr antibodies preceded the clinical onset of IDDM
by several years and sometimes even preceded the detection of
ICCA.
The detection of 64,000 Mr antibodies several years before
IDDM was clinically manifest lends support to the concept that
an autoimmune attack on ,3-cells may start long before the clin-
ical onset (25). Experiments in mice indicate that a critical
threshold of 80-90% loss of /-cells is needed before clinical
symptoms of diabetes develop (26). As described (11- 13) for
some of the patients studied here it is possible that a similar
progressive loss of ,8-cell function over a long period oftime has
also occurred before the clinical onset of IDDM.
The expression ofthe 64,000 Mr antibodies did not progress
linearly with time except in one patient. Therefore it is not known
how early the antibodies developed in the other positive indi-
viduals. In fact, the one patient followed for the longest period
had the strongest positive reaction in a sample obtained 91 mo
before clinical onset ofIDDM and became less positive in later
samples. Since the immune reaction seemed to diminish closer
to onset we speculate that a low 64,000 Mr immunoreactivity
detected in some patients may, in fact, reflect the end of an
autoimmune process, since antigen in sufficient amounts may
not be present to maintain an immune response. The data avail-
able for the IDDM patients and the first degree relatives with
abnormal glucose tolerance are inconclusive as to whether or
not 64,000 Mr antibodies were present before a decrease in /3-
cell function commenced. Only prospective analyses of 64,000
Mr positive individuals identified before any abnormalities in
(3-cell function, exemplified by the 64,000 Mr antibody positive
control sibling, may, given time, provide information as to the
order of events.
Isolated antigen is needed for specific and sensitive immu-
noassays for 64,000 Mr autoantibodies to determine how 64,000
Mr antibody titers relate to loss of /3-cells during a prediabetic
period. Such assays should also make it possible to determine
the prevalence of 64,000 Mr autoantibodies among healthy in-
dividuals with and without family history of IDDM in larger
population samples. Apart from the 21 healthy controls analyzed
in the present study, we have previously analyzed an additional
13 healthy individuals and only found one positive. The speci-
ficity of 64,000 Mr antibodies is also demonstrated by their ab-
sence in sera from 5 SLE patients and in 36 sera from patients
with diseases of the thyroid having no clinical signs of impaired
glucose tolerance. The analyses ofsuch material, which included
patients with high titers of nonrelated antibodies, did demon-
strate the importance of using a purified membrane protein
fraction to avoid background problems in the assay for 64,000
Mr antibodies. Furthermore, results using sera from patients 1,
1 1, and 12 indicated that very weak titers of64,000 Mr antibodies
may only be detected using purified material.
It is still unclear whether the 64,000 Mr determinant is ex-
pressed on the cell surface or primarily confined to the intra-
cellular compartment. The membrane protein characteristics of
the 64,000 Mr component were demonstrated by its partition
into the detergent phase of TN-1 14 (24). Furthermore in sub-
cellular fractionation of human islets, the protein is found in
the particulate fraction (Dr. M. Christie, unpublished results).
It was found that the 64,000 Mr antibodies were better correlated
to ICSA detected on purified rat islet /3-cells than to ICCA (4).
The demonstration of a plasma membrane expression of the
64,000 Mr protein by surface iodination was not possible due
to difficulties in disrupting human islets without damaging the
fragile endocrine cells. An unequivocal assignment of the 64,000
Mr antigen to the plasma membrane or intracellular membranes
has therefore not as yet been feasible.
In the present study the introduction of a novel highly sen-
sitive double fluorescence assay resulted in the detection ofICCA
in some individuals that had been negative using more conven-
tional assays. Comparison of ICCA and 64,000 Mr antibody
assay data showed discordance in two IDDM and one Hashi-
moto's disease patients. In theory since 64,000 Mr antibodies
are directed to a human islet cell protein they should also be
detectable by the ICCA assay, providing firstly, that it is sensitive
enough to detect antibodies to a minor membrane protein and
secondly that 64,000 Mr antigenic epitopes have not been de-
stroyed during preparation of pancreatic sections. However, by
the nature of immunofluorescence assays, sera may be positive
in an ICCA assay without containing 64,000 antibodies.
It was noted that 64,000 Mr antibodies were detected in early
samples oftwo patients which later became positive in the ICCA
assay, demonstrating that in these patients, the 64,000 Mr an-
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tibodies were the first detectable sign of an adverse immune
reaction to islet cells. The opposite, that patients were positive
in the ICCA assay before developing 64,000 Mr antibodies, was
not observed.
The function ofthe 64,000 Mr protein is presently unknown.
It was neither detected in 11 endocrine and nonendocrine human
cell lines (27), nor in freshly isolated human peripheral lym-
phocytes (4) and thyrocytes (S. Bawkkeskov, unpublished results)
indicating that its expression may be restricted to islet cells.
64,000 Mr antibodies were detected in all (-cell specific, ICSA
positive sera, tested on rat islets in a previous study (4) indicating
that the protein is expressed in Y-cells. Furthermore, a protein
of the same molecular mass has been specifically immunopre-
cipitated with IDDM sera from 13-cell tumors oftransgenic mice
(S. Bxkkeskov and D. Hanahan, unpublished results). An un-
equivocal assignment of the protein to human 13-cells requires
analyses ofpurified human 13-cells and such material is presently
not available.
The present data indicate that the 64,000 Mr protein anti-
bodies may appear long before the clinical onset ofIDDM. It is
suggested that this component may represent the primary target
protein in an autoimmune reaction against the Y-cells. A recent
controlled trial with cyclosporin A suggests that the length and
prevalence of remission in newly diagnosed IDDM patients are
increased (28). It is speculated that immune intervention may
rather result in a prevention ofIDDM if started before a major
loss of :-cells has occurred. Therefore, a simple, reliable, and
rapid assay using purified target autoantigen(s) are urgently
needed to detect islet cell antibody positive persons who are
potentially at risk of developing IDDM. We suggest that the
64,000 Mr protein may be a likely candidate for use in such
assays.
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